DPYD

OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics

Retrieved on: 
火曜日, 4月 2, 2024
FDA, Other Health, Practice Management, Pharmaceutical, Surgery, Managed Care, Oncology, Mental Health, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Toxicity, DPYD, Irinotecan, Clinical professor, PMID, UGT1A1, Risk, Mayo Clinic, Mental health, Wastewater treatment, Cancer, Doctor of Philosophy, MD, Medicine, E pluribus unum, Safety, Patient safety, Pain management, DPD, Colorectal cancer, Vomiting, Clinical Pharmacogenetics Implementation Consortium, Pharmaceutical industry

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.

Key Points: 
  • The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.
  • Using PGx can inform usage and dosage decisions for a wide range of chemotherapy and supportive care medications.
  • For more information about RightMed Oncology, please visit OneOmeInstitute.com/Oncology or reach out directly to discuss a PGx program for your health system.
  • OneOme aims to improve patient safety, reduce overall cost of care, and improve patients' health outcomes.

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

Retrieved on: 
火曜日, 11月 7, 2023
Knowledge, FDA, Medical genetics, American College, 23andMe, DPYD, Genetic testing, ACMG, Polygene, Biomarker, Health, Ovarian cancer, Therapy, Life, BRCA1, Reading, Genetics, Citalopram, Liver, Kidney, Research, Prostate cancer, Clinical Pharmacogenetics Implementation Consortium, Pharmacogenomics, Metabolism, Genomic Health, BRCA2, Genome, Heredity, Disease, LDL, CYP2C19, Risk, Asthma, Risk assessment, Cancer, Breast cancer, Saliva, Pancreatic cancer, PGS, Fetus, Gene, SLCO1B1, Anxiety, Breast, American College of Medical Genetics and Genomics, Lijun International Pharmaceutical (Holding) Co. Ltd., Cholesterol, SAN, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.
  • Members of Total Health will also receive all the reports and features offered in the Company’s existing 23andMe+ Premium Membership .
  • As part of Total Health, members will gain access to all the premium reports and features delivered through 23andMe+ Premium.
  • The 23andMe+ Total Health membership will cost $99 per month, billed in a one-time annual payment of $1,188.

Tempus Introduces a New, Predictive Diagnostic Test to Its Growing Collection of Algorithms

Retrieved on: 
火曜日, 10月 26, 2021
Oncology, Health, Medical Devices, Technology, Other Technology, Genetics, Biotechnology, HRD, Head, Technology, Cancer, Algorithm, Patient, Breast, Risk, Intelligence, Library, Â, Precision medicine, Collection, DPYD, Therapy, Health, Toxicity, Physician, Pharmaceutical industry, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests.
  • Tempus platform generates the type of rich sequencing data required to develop a novel class of predictive algorithms that can be introduced in the clinic to support personalized patient treatment.
  • In the case of DPYD, the test helps physicians to better identify patients at potential risk for toxicity to 5-FU/Capecitabine chemotherapy.
  • Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

OneOme Expands its Comprehensive Pharmacogenomic Test Offering with New Genes and Medications

Retrieved on: 
火曜日, 5月 22, 2018
Genomics, Pharmacology, Pharmacy, Methylenetetrahydrofolate reductase, Cytochrome P450, Pharmacogenomics, Health, CYP2C19, DPYD, UDP glucuronosyltransferase 1 family, polypeptide A1, Biology

In addition to these updates, OneOme now gives providers the option to order the MTHFR gene as a complimentary add-on to the RightMed test.

Key Points: 
  • In addition to these updates, OneOme now gives providers the option to order the MTHFR gene as a complimentary add-on to the RightMed test.
  • "With these enhancements to our product, OneOme is continuing to make progress toward providing the highest quality, most cost-effective and clinically relevant pharmacogenomic solution for patients and providers across the globe," said Paul Owen, CEO of OneOme.
  • "Adding HLAs to our comprehensive panel has been a goal since the very beginning," said Ross Higgins, director of laboratory operations and clinical development at OneOme.
  • In addition to updates to its RightMed product, OneOme now offers single gene tests for DPYD, UGT1A1, CYP2C19, and MTHFR.